Home › Funds › SAMLYN CAPITAL, LLC › DYN

SAMLYN CAPITAL, LLC position in DYN

DYNE THERAPEUTICS INC · Health Care

SAMLYN CAPITAL, LLC reported holding 1,754,708 shares of DYN (DYNE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$39.0M, representing 0.64% of its reported portfolio and ranking #50 among its reported holdings. SAMLYN CAPITAL, LLC has disclosed DYN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)1.75M sh
Reported value held$38.97M
Portfolio Weight0.64%
First reportedQ4 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How SAMLYN CAPITAL, LLC's DYN position evolved

SAMLYN CAPITAL, LLC first disclosed a stake in DYN in Q4 2025 at 1,493,075 shares (US$29.2M). The position peaked in Q2 2026 at 1,754,708 shares, worth US$39.0M. Across 3 filings, SAMLYN CAPITAL, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,754,708 shares valued at US$39.0M — a reduction of -167,835 shares quarter over quarter.. Notable position changes include a 29% increase in Q1 2026 (shares rose 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 1.49M $29.20M New
Q1 2026 1.92M $34.86M Add
Q2 2026 1.75M $38.97M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DYN and 13F data

DYN (DYNE THERAPEUTICS INC) is a Health Care company. 41 other funds we track also report a position in DYN — the largest reported positions include Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DYN

All DYN fund holders →

FAQ

How long has SAMLYN CAPITAL, LLC held DYN?

SAMLYN CAPITAL, LLC has disclosed DYN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is SAMLYN CAPITAL, LLC's current position in DYN?

As of Q2 2026, SAMLYN CAPITAL, LLC holds 1.75M shares of DYN (DYNE THERAPEUTICS INC), valued at $38.97M, representing 0.64% of its reported portfolio and ranking #50.

Has SAMLYN CAPITAL, LLC been buying or selling DYN?

In the latest 13F filing (Q2 2026), SAMLYN CAPITAL, LLC reduced its position in DYN. The position peaked in Q2 2026 at 1.75M shares.

Which other funds hold DYN?

Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.